Compass Pathways Completes Target Administration Of Psilocybin Therapy In World’s Largest Study
Compass Pathways (Nasdaq: CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression.